Article
[BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion - 1 Apr 2011
Cañadas Garre Marisa, López de la Torre Casares Martín, Becerra Massare Patricia, López Nevot Miguel Ángel, Villar Del Moral Jesús, Muñoz Pérez Nuria, Vílchez Joya Ricardo, Montes Ramírez Rosa, Llamas Elvira José Manuel
Abstract excerpt
BACKGROUND AND OBJECTIVE: The BRAF(T1799A) mutation is reported to be associated to aggressive, persistent, and recurrent tumor in papillary thyroid carcinoma (PTC) patients. Association of the BRAF(T1799A) mutation in the primary tumor with the clinicopathological characteristics of PTC patients was analyzed. PATIENTS, MATERIAL AND METHODS: Ninety-seven PTC patients were followed up for a median of 64.1 months....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.